Nonobese diabetic (NOD) mice spontaneously develop an autoimmune diabetes resembling human insulin-dependent diabetes mellitus (IDDM). Several lines of evidence suggest that T cells are responsible for mononuclear cell infiltration into the islets (insulitis) and destruction of beta cells in NOD mice. Disease transfer studies have shown that both splenic CD4 and CD8 T cells from diabetic NOD mice are necessary to transfer diabetes to newborn or sublethally irradiated NOD mice [1, 2] and islet-specific CD4 and CD8 T-cell clones are both required before significant insulitis develops in irradiated NOD mice [3] . However, islet-specific CD4 T-cell clones have been found to cause diabetes when injected into unmanipulated young NOD mice [4] or NOD F1 mice [5] . In addition, CD4 T cells from diabetic NOD donors have also been shown to transfer disease into NOD-severe combined immunodeficient (scid) mice
in which normal development of functional lymphocytes is prevented [6] . These findings may indicate that CD4 T cells are essential for development of diabetes, because they play an important role in disease initiation and they activate and recruit CD8 T cells as the final effector in the destruction of beta cells in NOD mice. However, in order to induce CD4 T cellmediated autoimmunity against beta cells, putative autoantigen(s) must be released from the beta cells, processed and presented by the antigen-presenting cells (APC). The important role of CD8 T cells in the initiation of autoimmune diabetes has been supported by recent observations that b 2-microglobulindeficient NOD mice developed neither insulitis nor diabetes [7, 8] , and CD8 T-cell clones from young NOD islets could rapidly transfer diabetes in irradiated NOD and NOD-scid mice in the absence of CD4 T cells [9] .
In the present study, we established an optimally activated H-2K d -restricted CD8 cytotoxic T-cell clone from NOD islets using different procedures from other islet-specific CD8 T-cell clones previously reported [9, 10] . Using this CD8 T-cell clone, we tried to transfer diabetes into NOD and several scid mice under various conditions by changing the number of donor cells and the age of recipients.
Materials and methods
Mice. NOD/Shi/Kbe mice were maintained in the Institute for Experimental Animals, Kobe University School of Medicine. The original colony was kindly supplied by Aburahi Laboratories (Shionogi Research Institute, Shiga, Japan). In our colony, insulitis becomes noticeable in most mice at 4-6 weeks of age, and the incidence of insulitis increases with age and reaches 95-100 % in both sexes at 20 weeks of age. The cumulative incidence of diabetes at 30 weeks of age was 65 and 5 % for female and male NOD mice, respectively. NOD-scid, BALB/cscid, CB17-scid, and C57BL/6-scid mice were a kind gift of Dr. K. Hioki (The Central Institute of Experimental Animals, Kawasaki, Japan). All animals were maintained in a filtered air environment and fed with autoclaved water and food. Various scid mice were treated with a sulfamethoxazole/trimethoprim mixture (Shionogi, Tokyo, Japan) in drinking water for 3 days per week to prevent infection by pneumocystis carinii.
Generation of islet-specific CD8 T-cell clones. CD8 T-cell lines
were generated from lymphocytes infiltrating islets from 20-week-old acutely diabetic female NOD mice. Isolated islets were cultured with RPMI 1640 medium including 1 % syngenic serum and 0.5 U/ml recombinant interleukin-2 (rIL-2) (kindly provided by Takeda Pharmaceutical Inc., Osaka, Japan). After 7 days' culture, 1 × 10 4 proliferated lymphocytes were restimulated with 20-30 mitomycin C (MMC)-treated NOD islets and 2 × 10 5 MMC-treated NOD spleen cells in 200 m l IL-2-free RPMI 1640 medium in each well of round bottomed 96-well microculture plates (Corning Coster Co., Cambridge, Mass., USA). After 2 days' stimulation, rIL-2 was added to the wells in a final concentration of 0.5 U/ml to expand lymphocytes. Every 2 weeks, CD4 T cells were deleted from expanded lymphocytes using an anti-CD4 monoclonal antibody (mAb) (GK1.5; ATCC, Rockville, MD., USA), and anti-rat IgG-conjugated magnetic beads (BioMag; Advanced Magnetic Inc., Cambridge, Mass., USA). After 2 to 3 cycles of restimulation, CD8 T-cell lines were cloned by limiting dilution. CD8 T cells were seeded at 1 cell per well in 96-well culture plates containing 10 MMC-treated NOD islets and 2 × 10 5 MMCtreated NOD spleen cells in RPMI 1640 medium supplemented with 10 % fetal calf serum (FCS) and 0.5 U/ml rIL-2. Cloned lymphocytes were repeatedly stimulated and expanded by rIL-2 and checked CD8 molecules by flow cytometric analysis. One CD8 T-cell clone (YNK1.3) was selected for this experiment because of its stable proliferation and higher cytotoxicity. Another CD8 T-cell clone (YNK2.1) which lost its cytotoxic activity for NOD islet cells and NOD-derived insulinoma cells during cell culture served as control. 3 Hthymidine incorporation was measured by a liquid scintillation counter and data are expressed as the mean ± SD of three different experiments.
Flow cytometry. YNK1.3 cells were stained by antibodies against various cell surface molecules; anti-CD25 (anti-IL-2 receptor, 7D4, ATCC), anti-a4-integrin (R1-2), anti-CD28, antib 7-integrin, anti-CD69 (PharMingen, San Diego, Calif., USA), and anti-CD54 (KAT-1) mAbs [11] . FITC-conjugated antimouse IgM (Cappel, Westchester, Penn., USA) was used for anti-CD25, FITC-conjugated anti-hamster antibody (Cederlane, Homby, Ontario, Canada) for anti-CD28, and FITC-conjugated anti-rat IgG (Cappel) for anti-a4-integrin, anti-b7-integrin, anti-CD69, and anti-CD54 mAbs. Cells (1 × 10 6 ) were incubated with Ca, Mg-free Hanks balanced salt solution with 1 % FCS and 0.1 % sodium azide for 30 min at 4°C and subsequently incubated with relevant second antibodies in indirect staining. Fluorescence intensity was analysed on an FACS 440 flow cytometer (Becton Dickinson, San Jose, Calif., USA).
Adoptive transfer of diabetes by CD8 T-cell clones.
Female NOD mice (7-28-day-old), NOD-scid mice (7-21-day-old), BALB/c-scid mice (7-14-day-old), CB17-scid mice (7-dayold), or C57BL/6-scid mice (7- Administration of anti-adhesion molecule mAbs to CD8 T-cell clone-induced diabetes. Seven-day-old NOD mice were injected intraperitoneally with 500 m g of either R1-2; anti-a4-integrin and M/K2; anti-vascular cell adhesion molecule-1 (VCAM-1) mAbs [13] or KAT-1; anti-intercellular adhesion molecule-1 (ICAM-1) and KBA; anti-leukocyte function-associated antigen-1 (LFA-1) mAbs [14] ) were preincubated with 10 m g/ml relevant mAbs for 30 min at 4°C before injection into corresponding mAbspretreated NOD recipients. Diabetic incidence was monitored up to 7 days after transfer and pancreatic insulitis of four mice in each group was evaluated at 3 days after transfer. The severity of insulitis was assessed by using the scoring system as follows [13, 14] : 0) normal islets; 1) mononuclear cell infiltration in less than 25 % of the islets; 2) 25-50 % of the islet infiltrated; 3) over 50 % infiltrated; 4) small retracted islets with few mononuclear cells.
Statistical analysis of diabetes incidence was determined with
Fisher's exact method. Statistical analysis of insulitis score was made by the non-parametric Mann-Whitney U-test.
Results

Characteristics of CD8 T-cell clone.
Proliferative responses of CD8 T-cell clone (YNK1.3) to the islets from various strains of mice and insulinoma cell lines were determined by 3 H-thymidine uptake ( Fig. 1 ). YNK1.3 cells responded well to NOD islets, BALB/c islets, and NOD-derived insulinoma MIN6-N8 a with stimulation indices (mean cpm in the presence of antigen/mean cpm without antigen) over 15. However, this clone did not respond to NOD spleen cells, C57BL/6 islets, and B6-derived insulinoma MIN6. As previously reported [14] gradually diabetic during 6 weeks after transfer. However, only 1 of 6 NOD mice became diabetic when 1 × 10 6 YNK1.3 cells were administered at 7-daysold. The non-cytolytic CD8 T-cell clone (YNK2.1, 1 × 10 7 ) failed to induce diabetes in NOD mice even when administered at 7 days of age (Table 1) .
In order to estimate the difference in diabetogenesis of the CD8 T-cell clone at the different ages of NOD mice, histological analysis was performed. Massive and diffuse infiltration of mononuclear cells into the islet was observed and some islets exhibited almost complete destruction in NOD mice which received 1 × 10 7 YNK1.3 cells at 7 days of age and killed at 36 h after transfer (Fig. 3A) . In contrast, in the pancreas from NOD mice which received 2 × 10 7 YNK1.3 cells at 21 days of age, the infiltration of mononuclear cells was also found, but it was not significant and limited to the peripheral site of the islets (Fig. 3B) .
To demonstrate that the islet-reactive CD8 T-cell clone itself infiltrated into the NOD islets directly after intraperitoneal administration, YNK1.3 cells were labelled with a fluorescent dye, PKH2, and 1 × 10 7 cells were injected into 7-day-old NOD mice. Fluorescent dye-labelled YNK1.3 cells accumulated in the islets and occupied the dominant population of infiltrating mononuclear cells at 36 h post-transfer (Fig. 3C) . A few labelled cells were found in the spleen, but not in the liver and kidney (data not shown). These results suggest that CD8 T-cells in sufficient number have the ability to rapidly and specifically accumulate in the islets of NOD mice at 7-10-days-old.
Adoptive transfer of diabetes in various scid mice by CD8 T-cell clone.
To eliminate the influence of endogenous T cells in the recipient mice, various scid mice were used as recipients. Five of 9 NOD-scid mice became rapidly diabetic within 5 days after cell transfer, when they received 1-2 × 10 7 YNK1.3 cells at 7 days of age ( Table 2) . None of the 4 non-diabetic recipients became diabetic until 7 weeks of age. Histological examination demonstrated extensive and diffuse lymphocytic infiltration in the islets from Figure 4 summarizes the time course of diabetes induction in 7-day-old NOD and NOD-scid mice after administration of various numbers of YNK1.3 cells. The incidence of CD8 T-cell clone induced diabetes was clearly dependent on number of donor cells in NOD recipients. In addition, lower incidence and slightly delayed onset of diabetes were observed in NOD-scid recipients as compared to NOD recipients. ) could transfer diabetes in BALB/c-scid (3/4) and CB17-scid mice (6/12) when administered at 7 days of age, but not in C57BL/6-scid mice (0/10) at the same age. Again, 1 × 10 7 of this clone could not induce diabetes in 14-day-old BALB/c-scid mice (0/6) by 7 weeks of age. These results suggest that YNK1.3 cells have the ability to rapidly induce diabetes not only in NOD mice but also in scid mice matched for H-2K d .
Effect of mAbs against adhesion molecules on adoptive transfer of diabetes.
To elucidate the role of adhesion molecules in the migration of CD8 T-cell clones into pancreatic islets, antibodies against these 3) at the indicated age. Diabetes was defined as 2 consecutive days of hyperglycaemia (plasma glucose > 16.7 mmol/l). Mice that did not develop overt diabetes were observed at least 42 days after transfer molecules were administered into 7-day-old recipient NOD mice before injection of YNK1.3 cells (Table 3). When mAbs against a 4-integrin and VCAM-1 were pretreated in recipient mice, both the severity of insulitis and the incidence of diabetes were not decreased. On the other hand, treatment of anti-ICAM-1 and anti-LFA-1 antibodies did not prevent a severe infiltration of YNK1.3 cells to pancreatic islets but decreased the incidence of diabetes. These results suggest that functional molecules related to transendothelial migration of lymphocytes are not involved in the infiltration of CD8 T-cell clones into pancreatic islets in 7-day-old NOD mice and that ICAM-1/LFA-1 interaction may contribute to the destruction of beta cells after transfer of CD8 T cells.
Discussion
In the present study, the CD8 T-cell clone, YNK1.3, which is restricted by H-2K d , was able to rapidly transfer overt diabetes not only in NOD mice but also in NOD-scid, BALB/c-scid, and CB17-scid mice. Since YNK1.3 cells in sufficient number transfered diabetes both in unmanipulated NOD mice within 4 days of cell transfer and in MHC class I-compatible scid mice that lacked functional endogenous lymphocytes, it is unlikely that CD4 T cells: 1) are activated by APC presenting specific autoantigens released from islet cells damaged by CD8 T cell clones; 2) produce IL-2 and interferon (IFN)-g, and; 3) activate and recruit more CD8 T-cells. This is supported by the fact that fluorescent dye-labelled CD8 T cells extensively accumulated in the islets and appeared to be mainly composed of islet-infiltrating mononuclear cells. However, in comparison with a study using NOD mice as recipients, lower diabetes incidence and slightly delayed diabetes onset as observed in H-2K d -matched scid mice might indicate the significant contribution of endogenous T and B cells especially CD4 T cells to beta-cell destruction even in such a short period. As previously reported, NOD islet-derived CD8 T-cell clones stimulated with NOD islet cells alone could transfer diabetes only in the presence of CD4 T cells [10] , whereas the present study has shown that the CD8 T-cell clone (YNK1.3) generated by the stimulation with NOD islet cells and MMC-treated NOD spleen cells (acting as APC) rapidly induced diabetes in NOD mice in the absence of CD4 T cells. Recently, Wong et al. reported that when islet-specific CD8 Tcell clones derived from islet-infiltrating cells of 7-week-old NOD mice were optimally activated in the presence of the co-stimulator B7-1 expressed on pancreatic beta cells, these CD8 T-cell clones could very rapidly cause diabetes in irradiated female NOD, NOD-scid and CB17-scid mice in the absence of CD4 T cells [9] . Therefore, if diabetes transfer must be successfully achieved by CD8 T cells alone, enough optimally activated islet-specific CD8 T cells must be administered. If neither islet-specific CD8 T cells were optimally activated nor enough numbers of the cells to induce the rapid destruction of beta cells and overt diabetes, migrated to the islet, CD8 T cells could not expand and be maintained in the absence of CD4 T cells. This is supported by the finding that 5 × 10 m g/ml relevant mAb for 30 min at 4°C and then transferred into corresponding mAb-pretreated NOD recipients. Diabetic incidence was monitored up to 7 days after transfer and the degree of pancreatic insulitis of four mice in each group was evaluated at 3 days after transfer. Insulitis score was presented as the mean ± SD. No difference was observed between insulitis score of each group (Mann-Whitney U-test). a p < 0.05 compared with diabetes incidence of YNK 1.3-transferred mice without antibody (Fisher's exact method) induce diabetes in 7-day-old NOD-scid mice even during the long-term observation period. Furthermore, immunohistological study revealed that in addition to CD8 T cells, CD4 T cells also accumulated in the islet lesion of recipient NOD mice at 4-7 days after transfer of 5 × 10 6 YNK1.3 cells. At 20 days after transfer, dominant CD4 T cells and a smaller number of CD8 T cells were observed as seen in adult NOD inflammatory islets. When anti-CD4 mAb was administered to these recipient NOD mice before transfer, neither insulitis nor overt diabetes was observed (data not shown). In the natural course of insulitis and diabetes in NOD mice, it might be suggested that a few autoreactive CD8 T cells initially destroy a part of the beta cells, resulting in the release of beta-cell specific autoantigens. These autoantigens are processed by regional macrophages and/or dendritic cells in the islets and presented to CD4 Th1 cells. The autoreactive CD4 Th1 cells exert a direct effect on betacell destruction by inflammatory cytokines to induce tissue damage, and recruit and activate direct effector cells including CD8 T cells and macrophages.
A unique phenomenon observed in the present study is the age-dependent susceptibility of CD8 Tcell clone to islet cells. YNK1.3 rapidly induced diabetes not only in 7-10-day-old NOD mice but also in 7-day-old NOD-scid, BALB/c-scid and CB17-scid mice. However, these strains of mice at 14 days of age or older were highly resistant to CD8 T-cell clone induced diabetes. Similar findings were reported by Bendelac et al. [1] ; the susceptibility of NOD recipients to diabetes transfer by bulk splenic T cells from NOD donors was limited to the first week of life and declined after 3 weeks of age. Peterson et al. [15] also reported that islet-specific CD4 T-cell clones were diabetogenic in 8-18-day-old NOD mice, while NOD mice, 19 days or older, were completely resistant to CD4 T-cell-clone induced diabetes. In contrast to CD4 T-cell clones, there are few reports of CD8 Tcell clones generated from NOD mice, since CD8 Tcell clones are difficult to isolate and maintain. Therefore, there are no reports on the effect of recipient's age on the induction of diabetes by islet-specific CD8 T-cell clones. The reason for the age-dependent susceptibility of recipients to the CD8 T-cell-induced disease may be related to both activation status of donor cells and pancreatic architecture or unique immune status of very young recipients. Activated status of CD8 T cells could be important for the migration into pancreatic islets and the destruction of beta cells. Recent reports demonstrate that lymphocytic inflammation is mediated largely by LFA-1/ICAM-1 and very late antigen-4 (VLA-4; a 4/b1-integrin)/ VCAM-1 interactions [16, 17] . Significant contribution of these two pairs of adhesion molecules to autoimmune inflammation of pancreatic islets in NOD mice was also reported [14, [18] [19] [20] [21] [22] . YNK1.3 cells expressed the activation marker CD25 and the adhesion molecule LFA-1, ICAM-1, but not CD28, CD69 and a 4-integrin. The loss of expression of a 4-integrin on our CD8 T-cell clone may account for the age-dependent susceptibility to islet cells. Wong et al. [9] reported that their islet-specific CD8 T-cell clones activated optimally by B7-1-expressed islet cells rapidly induced diabetes in irradiated 7-week-old female NOD, 2-3-week-old female NOD-scid and CB17-scid mice. Both their CD28 + CD8 clones and our CD28 -CD8 clones transfered diabetes in the absence of CD4 T cells. Different from their CD8 clones, those generated in the present study could not transfer diabetes into irradiated 7-week-old NOD mice (data not shown) and 3-week-old NOD scid mice. Activated status of CD8 clones might determine the ability to migrate into the pancreatic islets. Their CD8 T-cell clones expressed not only ICAM-1 but also a 4-integrin. Therefore, a possible migration of our CD8 T-cell clone into the islets not in 14-day-old or older but in 7-10-day-old NOD mice, suggests that LFA-1/ICAM-1 interaction rather than VLA-4/ VCAM-1 pathway may be more important in the migration of CD8 T cells to very young NOD islets. However, not only anti-a4-integrin/VCAM-1 mAb but also anti-LFA-1/ICAM-1 mAb pretreatment in 7-day-old recipients could not block the pancreatic islet infiltration of YNK1.3 cells. These results suggest that functional transendothelial migration, in which LFA-1/ICAM-1 and a 4-integrin/VCAM-1 pathways are involved, may not contribute to CD8 T-cell infiltration to pancreatic islets in very young mice.
Unique pancreatic architecture and islet neogenesis of very young mice may contribute to more easy trafficking of activated CD8 T cells to the islets than adult mice. The pancreas of very young mice around 1-2 week of age shows several distinctive features as compared with adults. A smaller size of islets and a loose arrangement of exocrine and endocrine glands were observed in very young mice (our histological observation). In addition, it has been recently reported that the microvasculature of target tissues expresses antigens that strongly affect cytotoxic T lymphocyte (CTL) access to tissue antigen. The vasculature displaying a continuous endothelium and basement membrane constitutes an extremely effective barrier that precludes CTL access to tissue antigen [23] . A recent study revealed that CD8 CTL clones from NOD mice could infiltrate into NOD islet grafts under the renal capsule within 1 week after transplantation, but not thereafter, indicating that the fenestrated barrier on capillary endothelia of islet grafts, prior to establishing complete revascularization, might result in the migration of CTL [24] . It may be speculated that the islet-specific CD8 CTL clone could be rapidly accessible to pancreatic islets of mice before 14 days of age when the epithelial tissue still does not contain intact microvascular endothelium in the process of maturation. Once a continuous layer of endothelial cells is etablished in the pancreas of mice older than 14 days, the vascular barrier must be breached by other factors. Before CD8 CTL gain access to islet beta cells, inflammatory changes probably mediated by islet-specific CD4 T cells may be necessary. In addition, the study in differentiation and development of the pancreas in mice revealed that the concentration of g -aminobutyric acid (GABA) in the pancreas reached a peak on postnatal day 7 and then decreased to the adult level on postnatal day 45. The large perinatal GABA concentration in the pancreas correlates with the time span during which islet neogenesis is most active [25, 26] . This finding may also be related to favourable CD8 T-cell access to islet cells in mice around 7 days of age.
Recent studies suggest that CD8 T cells play an important role in the initiation of autoimmune insulitis in NOD mice [27] . Initial cells infiltrating pancreatic islets of NOD mice were reported to consist of CD8 T cells and macrophages [28] . b 2-microglobulin-deficient NOD mice fail to develop insulitis and overt diabetes, whereas splenic T cells from diabetic NOD mice can transfer insulitis and diabetes to these b 2-microglobulin-deficient NOD mice [7, 8] . Our recent studies revealed that CD8 CTL established from NOD islets showed a strong LFA-1/ICAM-1-dependent cytotoxicity against islet cells [14] , and that short-term blockade of the LFA-1/ICAM-1 pathway in very young NOD mice resulted in the longlasting complete protection of insulitis and spontaneous diabetes [22] . Prevention of CD8 CTL-induced diabetes by anti-LFA-1/ICAM-1 mAbs treatment (Table 3 ) may account for the inhibition of direct islet-cell destruction by CD8 CTL, resulting in the abrogation of the subsequent autoimmune responses against pancreatic islets. Further study is necessary for evaluating the initial immune responses against islet cells in NOD mice.
